Consolidated Expenses Statement from Research Projects financed by Federal Funds from the United States of America, through contracts and subcontracts signed between Universidad Peruana Cayetano Heredia and National Institute of Health (NIH) and universities of the United States of America, respectively, for the period from January 1, 2017 to 31 December of 2017



Consolidated Expenses Statement from Research Projects financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America For the period from January 1 to December 31, 2017

Content

Executive summary

Background of the Entity and the Project Objectives of the audit Scope of the audit Results of the audit Agreed upon procedures Comments by the entity

Review of the Consolidated Expenses Statement of the Research Projects

Independent auditor's report Consolidated Expenses Statement Note to the Consolidated Expenses Statement

Report on the evaluation of internal control

Independent auditor report Recommendations on issues of internal accounting control and others

Report on the compliance of the cooperation agreement terms

Independent auditors report Status of compliance of the cooperation agreement terms

Audit Report of the Consolidated Expenses Statement from Research Projects financed by Federal Funds from The United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of

America

For the period from January 1 to December 31, 2017

1. Background of the Entity and Research Projects

The Entity

Universidad Peruana Cayetano Heredia (hereinafter the University) was incorporated in the city of Lima, Peru, as a legal nonprofit entity, of private law, with autonomy of academic, administrative, economic and policy Government, created under the auspices by the Supreme Decree No. 018 from December 22, 1961. The University is governed by the law N ° 30220 "University Law", as well as by its own statute, the records of meetings of the University Assembly, the minutes of the University Council and by its internal policies.

As of December 31, 2017, the University maintains the subsidiaries, Clinica Medica Cayetano Heredia S.A., Bioincuba S.A.C., and Agency Operator Cayetano Heredia S.A., domiciled in Peru, in which owns the following participation 60.67%, 99.99% and 99.99%, respectively.

Research Projects:

Research Projects, hereinafter 'The Projects' maintained for Universidad Peruana Cayetano Heredia for the period from January 1, 2017 until 31 December 2017 are the following:

Project 1: Peru Infectious Diseases Epidemiology Research Training Consortium Project 2: Optimizing ring screening strategy for control of taenia solium infection Project 3: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Epidemiology of Malaria in the Peruvian and Brazilian people) Project 4: HIV Prevention and Care for Peruvian MSM and Transgender Women Project 5: Training in Infectious Diseases in Peru - Time for Capacity Strengthening in Clinical Research (Training in Parasitic Diseases and Central Nervous System infections) Project 6: PARACAS: Program for Advanced Research Capacities for AIDS in Peru Project 7: Kuskaya: An Interdisciplinary Training Program for Innovation in Global Health Project 8: Combined Albendazole and Praziguantel in Subarachnoid NCC, CCC, Lead application Project 9: 1/2-Regional Geohealth Hub Centered in Peru - Peru Project 10: Latin America Treatment & Innovation Network in Mental Health (LATIN-MH) Project 11: Tuberculosis Trials Consortium (TBTC) Project 12: Improving Diagnostic and Management Tolls for Neurocysticercosis (Peru -JHU TMRC Program) Project 13: Characterization of hippocampal sclerosis in individuals with calcified Neurocysticercosis

Project 14: Placental Colonization by Treponema Pallidum, Congenital Syphilis & Novel Vaccine Project 15: Liver cystic echinococcosis: Pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection) Project 16: Predicting Risk of Human Leptospiros by Environmental Surveillance Project 17: Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community Project 18: Use of bisphosphonates to reduce the calcification process in animal models of cysticercosis Project 19: Strengthening and consolidating Resources for VIH Prevention in the Peruvian Military Project 20: Translational Research Development for Endemic Infectious Diseases of Amazonia Project 21: Impact of Fascioliasis among Children in the Peruvian Highlands Project 22: Implementation of foot thermometry and SMS to prevent diabetic foot ulcer Project 23: TOD@S (Transforming Ourselves through Dialogue, Organizing, and Service): An Anti-Violence Program for Transgender people in Peru Project 24: International Prospective Observational Cohort Study of Sika in Infants and Pregnancy (ZIP staudy) Project 25: Disrupting Vector-Borne Desease Transmission in Complex Urban Environments Project 26: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Core B Data Management -ICEMR) Project 27: Improving participation in vector controls campaigns through behavioral economics Project 28: Lactoferrin for Prevention of Sepsis in Infants Project 29: Evaluating Corraling nad the Effect of Dung Beetles on Transmission and Control of Cysticercosis Project 30: Infectious Diseases Training Program in Bolivia: South - South Training with Peru Project 31: Prevalence and Incidence of Neonatal HSV (Herpes Simplex) in Pre-term Infants Project 32: Assesing how Relationships between MSM influence HIV Prevention Strategies Project 33: Runachay: Information and Communication Technologies for Global Health Research Project 34: Combined Albendazole Plus Praziguantel in Subarachnoid NCC, DCC Application Project 35: Syphilis: Translating technology to understand a neglected epidemic Project 36: Human Inmmune Signatures of Dengue Virus and Mycobacterium Tuberculosis exposure in Infection, Disease and Vaccionation Project 37: Addressing the Global Burden of Leptospirosis in Two Endemic Countries Project 38: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Interaction between Human-Plasmodium Mosquito in the Transmission of Malaria) Project 39: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Shared Laboratory resource -Core C - ICEMR) Project 40: CCASAnet: Caribbean, Central and South America Network Project 41: Oxfendazole as a Broad Spectrum Deworming Medicine in Humans: Phase II Efficacy Study in Geohelminths Project 42: ICTUS: Interdisciplanary Cerebrovascular Diseases Training Program in South America Project 43: Predictors of Cardiomypathy Progression in a Chagas Disease Cohort in Bolivia

Project 44: CHAKA: Strengthening Research Support Structures in the Andean Region

Project 45: Multidisciplinary Training Program on Neuropsychiatry and Behavioral Disorders in First Nations (NEUFIN)

Project 46: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Core A Training - ICEMR) Project 47: Inter-American Training for Innovations in Emerging Infectious Diseases

Project 48: 2/2 - Regional Geohealth Hub Centered in Peru - US

Project 49: Structural Behavioral HIV Prevention for Male Sex Workers in Peru - Planning a Skil-Building Program to Prevent HIV in Male an Transgender)

Project 50: Center for HIV Identification, Prevention and Treatment Services (CHIPTS) - Link your life: Linkage and Retention in Care for PLH

Project 51: University of California Global Health Institute Program for Fellows and Scholars Project 52: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Transmission Dynamics of Residual Malaria in the Amazon)

Project 53: Inter-American E-Capacity Research Training in Infectious and Chronic Diseases Project 54: Drug Discovery for Mental Disorders: Preclinical Studies of Peruvian Botanicals Project 55: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Spatiotemporal Adaptation of Anopheles Darlingi in Diverse Ecological)

Project 56: Fogarty Global Health Fellows Cordinating Center (The UJMT Global Consortium: Building Research Capacity through Mentored Training)

Project 57: Alternative Venues tor HIV Testing with MSM and TW in Lima, Peru

Project 58: Launching a Salt Substitute to Reduce Blood Pressure at the Population Level - Perú Project 59: Fogarty Global Health Fellows Coordinating Center (Metalproteinasas of the Extracellular Matrix (MMPS) in Patients)

Project 60: Genetic Susceptibility to HTLV-1 Related Deseases

Project 61: Kuskaya: An Interdisciplinary Training Program for Innovation in Global Health - HIV/STI Program Science Training Plan for Latin America

Project 62: Fogarty Global Health Fellows Coordinating Center

Project 63: Amazonian Center of Excellence in Malaria Research (Immunology of Asymtomatic Malaria and the Effects of Immunity on Plas)

Project 64: Amazonian Center of Excellence in Malaria Research (Core B - Data Management) Project 65: Effects of drug loading and associated factors on the occurrence of adverse drug reactions (ADRs) during the first six months of Highly Active Antiretroviral Therapy (HAART) at a referral hospital Project 66: Planning to Establish a Regional Center of NCD Research Training in Peru

Project 67: Mortality associated with the time of onset of highly active antiretroviral therapy (HAART) during the course of treatment for tuberculosis in a cohort of patients with HIV infection in Peru Project 68: Defining the patterns of antibiotic resistance among pneumococcal isolates in Peru Project 69: PARACAS Award: Need for Improvements in the Care Retention of Patients with HIV Infection in a Public Reference Hospital in Peru

These research projects are financed by Federal Funds of the United States of America, mainly from National Institute of Health - NIH, through contracts and subcontracts with Universidad Peruana Cayetano Heredia. These financings are made in two ways: directly between the UPCH and NIH; and indirectly, through a subcontract where NIH funds to a University in the United States of America and this subcontracts the UPCH research services.

2. Objectives of the audit

For the audit of the Consolidated Expenses Statement of the Research Projects financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH on universities of the United States of America for the period from January 1, 2017 to December 31, 2017, it the following objectives were set:

- Opinion on whether the consolidated expenses statement for the period from January 1, 2017, to December 31, 2017 of the Research projects financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America , reasonably presents the costs incurred, in accordance with the rules of generally accepted government audit in the United States of America, the supplement of compliance of the Office of administration and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISAs).
- Evaluate and obtain an adequate understanding of the internal control implemented by
 Universidad Peruana Cayetano Heredia to manage research projects, evaluate control risk and
 identify material weaknesses in internal control.
- Verify the compliance, by the Universidad Peruana Cayetano Heredia, with the Contract Terms of the Research Projects

3. Scope of the audit

The scope of the audit included the examination of the Consolidated Expenses Statement of the research Projects financed by Federal Funds from the United States of America, through direct contracts mainly with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America by the period from January 1 to December 31, 2017, and was performed in accordance with the standards of generally accepted governmental audit in the United States of America, the supplement of compliance of the Office of management and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISAs).

4. Results of the audit and agreed upon procedures

As a result of the audit and agreed upon procedures practiced to the Consolidated Expenses Statement of the Research Projects financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America for the period between January 1 and December 31, 2017, we issued our audit report, Memorandum of recommendation and report on Compliance with the terms of conditions of contracts of date August 8, 2018, which are summarized below:

Consolidated Expenses Statement-

We issued our audit opinion without reservations on the consolidated expenses statement for the period from January 1 to December 31, 2017 of the Research Projects financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America, in accordance with the accounting principles and practices described in note 2 to the Consolidated Expenses Statement.

Evaluation of internal control-

As a result of the execution of our audit procedures, we identified certain issues of internal control by which we issued a Memorandum of recommendations on the detected issues.

Compliance with the terms of contracts for Research Projects-

In the period from January 1 to December 31, 2017, the University complied with administrative financial provisions set out in the terms of conditions of contracts for the Research Projects.

5. Agreed upon procedures

Compliance with the terms of contracts for Research Projects-In the period from January 1 to December 31, 2017, the University complied with administrative financial provisions set out in the terms of conditions of contracts for the Research Projects.

6. Comments by the Entity

The Directorate General of Administration and the Projects Office of the University took cognizance of the report of audit on the Consolidated Expenses statement for the period from January 1 to December 31, 2017 of the Research Projects, the Memorandum of recommendation and the report on compliance with the terms of conditions of contracts financed by Federal Funds of the States United States, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of North America, expressing their agreement on its content.



Paredes, Burga & Asociados Sociedad Civil de Responsabilidad Limitada

Report of Independent Auditors on the Consolidated Expense Statement from research projects financed by Federal Funds from United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America

To the members of the Council University of Universidad Peruana Cayetano Heredia

We have audited the Consolidated Expenses Statement of sixty nine Research Projects of Universidad Peruana Cayetano Heredia which are financed by Federal Funds from the United States of America, through direct contracts mainly with National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America for the period from January 1 to December 31, 2017.

Project Management's Responsibility for the consolidated expenses statement

The Project Management of Universidad Peruana Cayetano Heredia is responsible for the preparation and reasonable presentation of the consolidated expenses statement in accordance with the accounting basis of the execution of the expense and the internal control as Project Management determines is necessary to enable the preparation of consolidated expenses statement that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on this consolidated expenses statement based on our audit. Our audit was performed in accordance with the rules of generally accepted government audit in the United States of America, the supplement of compliance of the Office of administration and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISAs). These standards require that we comply with ethical requirements and that we plan and perform the audit to obtain reasonable assurance that the consolidated expenses statement are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated expenses statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated expenses statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the University preparation and fair presentation of the consolidated expenses statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the consolidated expensed expenses statement.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the Consolidated Expenses Statement of the sixty nine Research Projects of Universidad Peruana Cayetano Heredia, presents fairly, in all material respects, the financial position of these Research Projects executed by Universidad Peruana Cayetano Heredia and financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities in the United States of North America for the period from January 1 to December 31, 2017, in accordance with the rules of generally accepted governmental audit in the United States of America, the supplement of compliance of the Office of management and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISAs).

Other matters

This report is intended for the exclusive use of Universidad Peruana Cayetano Heredia and of the National Institute of Health (NIH) and must not be distributed or used by third parties without the authorization of such entities.

Lima, Peru October 1, 2018

Paredes, Burga & Asociedos

Countersigned by:

Tania Arana C.P.C.C. Registration No. 28060

Consolidated Expenses Statement from Research Projects

For the period from January 1, 2017 to December 31, 2017

Research Projects	Benefits to employees US\$	Training US\$	Travel expenses US\$	Consultants US\$	Equipment and/or supplies US\$	Laboratory and patient care services US\$	Consortium US\$	Other US\$	Indirect costs US\$	Total US\$
Project 1	73,812	135,103	31,044	2,036	85,175	11,823	37,202	27,188	9,704	413,087
Project 2	175,379	-	53,622	-	52,237	18,441	-	76,947	23,585	400,211
Project 3	116,463	2,500	18,721	-	142,309	591	-	58,035	17,978	356,597
Project 4	213,809	670	11,375	1,471	15,440	24,492	-	53,122	23,385	343,764
Project 5	50,005	60,705	8,726	7,773	30,719	3,914	127,223	31,737	13,316	334,118
Project 6	82,271	53,311	5,788	-	10,840	131	117,307	41,333	16,364	327,345
Project 7	71,957	86,400	3,278	638	50	-	128,534	13,140	13,847	317,844
Project 8	148,879	-	17,253	30,194	16,568	46,496	26,739	23,764	5,862	315,755
Project 9	89,085	100	18,363	17,372	2,182	62	139,777	10,146	3,710	280,797
Project 10	209,683	-	2,230	-	2,550	4,647	10,376	13,168	-	242,654
Project 11	126,976	1,913	29,196	-	11,341	12,750	-	43,121	14,247	239,544
Project 12	112,600	2,350	23,682	26,032	28,521	10,684	-	18,094	7,720	229,683
Project 13	37,187	358	855	32,956	228	40,375	94,527	-	8,169	214,655
Project 14	137,100	3,940	18,421	370	22,513	2,616	-	11,547	14,991	211,498
Project 15	52,012	-	22,866	13,583	41,871	31,677	9,900	13,226	13,511	198,646
Project 16	89,974	213	8,265	-	40,779	758	-	48,834	5,355	194,178
Project 17	109,943	-	2,496	734	39,937	1,207	-	19,144	12,403	185,864
Project 18	77,989	250	3,111	13,496	15,126	3,355	-	26,671	10,822	150,820
Project 19	110,974	2,099	7,661	1,839	2,672	247	-	7,121	7,380	139,993
Project 20	17,993	68,391	23,946	-	7,500	-	-	14,711	49	132,590
Project 21	90,385	695	7,317	-	24,384	180	-	705	7,615	131,281
Project 22	33,291	-	612	-	88	4,491	86,815	523	47	125,867
Project 23	64,173	-	14,077	27,704	436	3,188	-	7,458	7,871	124,907
Project 24	38,244	1,129	5,016	-	18,999	-	47,307	7,424	3,949	122,068
Project 25	65,249	5,383	5,456	11,454	3,122	9	-	15,014	12,089	117,776
Project 26	97,989	-	3,804	-	3,983	-	-	1,183	2,140	109,099
Project 27	63,109	-	2,542	15,271	850	-	-	8,862	9,081	99,715
Project 28	6,864	947	1,154	6,484	9,238	-	-	59,266	2,362	86,315
Project 29	18,106	-	1,377	4,721	27,314	11,535	-	11,135	6,082	80,270
Project 30	24,875	5,714	1,664	-	9,640	-	-	21,201	8,603	71,697
Project 31	63,707	-	86	-	5,171	-	-	51	-	69,015
Project 32	25,517	-	3,026	2,525	2,121	8,857	-	20,125	3,944	66,115
Project 33	47,181	4,000	16	-	456	-	-	6,978	3,961	62,592
Project 34	22,910	-	5,720	1,916	1,620	366	14,515	5,890	6,005	58,942
Project 35	19,743	-	-	1,000	548	629	29,065	2,433	3,876	57,294

Consolidated Expenses Statement from Research Projects

For the period from January 1, 2017 to December 31, 2017

Research Projects	Benefits to employees US\$	Training US\$	Travel expenses US\$	Consultants US\$	Equipment and/or supplies US\$	Laboratory and patient care services US\$	Consortium US\$	Other US\$	Indirect costs US\$	Total US\$
Project 36	20,657	-	1,238	1,500	3,637	21,446	4,034	1,106	-	53,618
Project 37	38,377	-	4,780	-	1,789	2,249	-	193	-	47,388
Project 38	28,779	-	387	-	1,706	3,125	-	8,318	2,467	44,782
Project 39	16,099	-	1,103	-	21,742	1,581	-	58	2,871	43,454
Project 40	34,983	-	-	-	685	-	-	1,453	2,401	39,522
Project 41	19,471	-	-	14,000	361	-	-	-	1,386	35,218
Project 42	23,243	-	-	-	2,901	6,197	-	-	1,751	34,092
Project 43	18,439	-	178	-	11,858	-	-	995	2,223	33,693
Project 44	21,523	6,930	1,074	-	-	-	-	3,165	408	33,100
Project 45	2,977	11,460	14,883	-	125	-	-	51	2,636	32,132
Project 46	26,054	800	3,247	-	11	160	-	213	50	30,535
Project 47	21,048	-	846	-	3,449	-	-	4,690	2	30,035
Project 48	-	2,000	5,746	8,000	154	-	-	10,583	26	26,509
Project 49	8,447	-	841	4,454	367	-	-	10,860	4	24,973
Project 50	22,909	-	167	-	181	439	-	141	1,122	24,959
Project 51	2,637	12,379	505	-	4,336	231	-	3,952	383	24,423
Project 52	16,827	-	15	-	181	-	-	32	3,693	20,748
Project 53	1,760	-	-	-	9,140	-	-	3,297	4,090	18,287
Project 54	4,458	-	723	-	5,760	-	-	7,312	25	18,278
Project 55	10,507	5,000	-	-	-	-	-	-	1,700	17,207
Project 56	787	10,179	-	-	1,325	-	-	3,823	651	16,765
Project 57	4,402	-	700	-	-	8,944	-	1,808	889	16,743
Project 58	294	-	-	-	-	9,183	-	1,242	1,352	12,071
Project 59	-	-	-	-	6,481	-	-	624	1,846	8,951
Project 60	3,628	-	-	-	2,843	-	-	-	20	6,491
Project 61	-	1,488	4,943	-	-	-	-	-	-	6,431
Project 62	1,653	-	48	-	2,921	-	-	538	-	5,160
Project 63	3,578	-	-	-	-	-	-	-	1,473	5,051
Project 64	3,149	-	5	-	94	-	-	-	456	3,704
Project 65	2,471	-	28	-	-	196	-	51	-	2,746
Project 66	2,483	-	-	-	-	-	-	-	30	2,513
Project 67	2,200	-	-	-	-	-	-	-	-	2,200
Project 68	-	-	76	-	739	-	-	1,050	64	1,929
Project 69		694			99			<u> </u>		793
Total expenses	3,149,274	487,101	404,299	247,523	759,413	297,272	873,321	784,852	334,042	7,337,097

Notes on the Consolidated Expenses Statement of the Research Projects financed by Federal Funds from the United States of America, through direct contracts with the National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America

Period from January 1 to December 31, 2017

1. Entity and research projects' background

Universidad Peruana Cayetano Heredia (hereinafter the University) was incorporated in the city of Lima, Peru, as a legal nonprofit entity, of private law, with autonomy of academic, administrative, economic and policy Government, created the Supreme Decree No. 018 by December 22, 1961. The University is governed by the law N ° 30220 "University Law", as well as by its own statute, the records of meetings of the University Assembly, the minutes of the University Council and by its internal policies.

As of December 31, 2017, the University maintains the subsidiaries, Clinica Medica Cayetano Heredia S.A., Bioincuba S.A.C., and Agency Operator Cayetano Heredia S.A., domiciled in Peru, in which ows the following participation 60.67%, 99.99% and 99.99%, respectively.

The University provides academic services at the undergraduate level through its19 careers: Medicine; School of medical technology: Clinical Laboratory, Radiology, Therapy of Hearing, Voice and Language, Physical Therapy and Rehabilitation; Stomatology; Biology, Pharmacy and Biochemistry; Nutrition; Chemistry; Health Administration; Public Health and Global Health; Psychology; Initial Education; Primary Education; Veterinary Medicine y Zootechnics; Nursing and Occupational Therapy and Biomedical Engineering in partnership with Pontificia Universidad Católica del Perú. At the postgraduate level provides academic services such as specializations, master's degrees, doctorates, among others. In 2016, the University received the institutional accreditation of the International Institute for the Quality Assurance (IAC) in teaching and university management, becoming the first Peruvian University accredited internationally.

Also, the University carries out research and consultancy projects through agreements, which represent another of its strategic development lines. A unique feature of the University is the support that provides to research, having obtained many awards and achievements of its students, teachers and graduates. Resources for these activities are obtained from different local and foreign cooperating entities.

To develop its academic and research activities, the University has four campuses in San Martin de Porres, La Molina, Miraflores and Lurin, and two research centers located in Tumbes and Piura provinces.

The University has an average of 4,230 students in undergraduate level and 3,054 students in postgraduate level in 2017 (4,220 students in undergraduate level and y 3,232 students in post-graduate level in 2016).

The University complements its academic activities through two educational clinics:

- The Stomatology Clinic, which aims to complement the academic activities of the University and to support research projects that develop the academic departments of the Faculty of Stomatology; and
- The Veterinary Clinic that aims to complement the academic activities of the University and to support the research projects of the Faculty of Veterinary and Zootechnics.

The legal address of the University (University campus and educational clinics) is located in Av. Honorio Delgado No. 430, Urbanización Ingeniería, San Martín de Porres, Lima, Peru.

Research Projects:

Research Projects maintained by Universidad Peruana Cayetano Heredia for the period from January 1, 2017 until 31 December 2017 are the following:

Project 1: Peru Infectious Diseases Epidemiology Research Training Consortium Project 2: Optimizing ring screening strategy for control of taenia solium infection Project 3: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Epidemiology of Malaria in the Peruvian and Brazilian people) Project 4: HIV Prevention and Care for Peruvian MSM and Transgender Women Project 5: Training in Infectious Diseases in Peru - Time for Capacity Strengthening in Clinical Research (Training in Parasitic Diseases and Central Nervous System infections) Project 6: PARACAS: Program for Advanced Research Capacities for AIDS in Peru Project 7: Kuskaya: An Interdisciplinary Training Program for Innovation in Global Health Project 8: Combined Albendazole and Praziguantel in Subarachnoid NCC, CCC, Lead application Project 9: 1/2-Regional Geohealth Hub Centered in Peru - Peru Project 10: Latin America Treatment & Innovation Network in Mental Health (LATIN-MH) Project 11: Tuberculosis Trials Consortium (TBTC) Project 12: Improving Diagnostic and Management Tolls for Neurocysticercosis (Peru -JHU TMRC Program) Project 13: Characterization of hippocampal sclerosis in individuals with calcified Neurocysticercosis Project 14: Placental Colonization by Treponema Pallidum, Congenital Syphilis & Novel Vaccine Project 15: Liver cystic echinococcosis: Pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)

Project 17: Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community

Project 18: Use of bisphosphonates to reduce the calcification process in animal models of cysticercosis Project 19: Strengthening and consolidating Resources for VIH Prevention in the Peruvian Military Project 20: Translational Research Development for Endemic Infectious Diseases of Amazonia

Project 21: Impact of Fascioliasis among Children in the Peruvian Highlands

Project 22: Implementation of foot thermometry and SMS to prevent diabetic foot ulcer

Project 23: TOD@S (Transforming Ourselves through Dialogue, Organizing, and Service): An Anti-Violence Program for Transgender people in Peru

Project 24: International Prospective Observational Cohort Study of Sika in Infants and Pregnancy (ZIP staudy)

Project 25: Disrupting Vector-Borne Desease Transmission in Complex Urban Environments Project 26: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Core B Data Management -ICEMR)

Project 27: Improving participation in vector controls campaigns through behavioral economics Project 28: Lactoferrin for Prevention of Sepsis in Infants

Project 29: Evaluating Corraling nad the Effect of Dung Beetles on Transmission and Control of Cysticercosis

Project 30: Infectious Diseases Training Program in Bolivia: South - South Training with Peru Project 31: Prevalence and Incidence of Neonatal HSV (Herpes Simplex) in Pre-term Infants

Project 32: Assesing how Relationships between MSM influence HIV Prevention Strategies

Project 33: Runachay: Information and Communication Technologies for Global Health Research

Project 34: Combined Albendazole Plus Praziguantel in Subarachnoid NCC, DCC Application

Project 35: Syphilis: Translating technology to understand a neglected epidemic

Project 36: Human Inmmune Signatures of Dengue Virus and Mycobacterium Tuberculosis exposure in Infection, Disease and Vaccionation

Project 37: Addressing the Global Burden of Leptospirosis in Two Endemic Countries

Project 38: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Interaction between Human-Plasmodium Mosquito in the Transmission of Malaria)

Project 39: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Shared Laboratory resource - Core C - ICEMR)

Project 40: CCASAnet: Caribbean, Central and South America Network

Project 41: Oxfendazole as a Broad Spectrum Deworming Medicine in Humans: Phase II Efficacy Study in Geohelminths

Project 42: ICTUS: Interdisciplanary Cerebrovascular Diseases Training Program in South America Project 43: Predictors of Cardiomypathy Progression in a Chagas Disease Cohort in Bolivia

Project 44: CHAKA: Strengthening Research Support Structures in the Andean Region

Project 45: Multidisciplinary Training Program on Neuropsychiatry and Behavioral Disorders in First Nations (NEUFIN)

Project 46: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Core A Training - ICEMR) Project 47: Inter-American Training for Innovations in Emerging Infectious Diseases Project 48: 2/2 - Regional Geohealth Hub Centered in Peru - US

Project 49: Structural Behavioral HIV Prevention for Male Sex Workers in Peru - Planning a Skil-Building Program to Prevent HIV in Male an Transgender) Project 50: Center for HIV Identification, Prevention and Treatment Services (CHIPTS) - Link your life: Linkage and Retention in Care for PLH Project 51: University of California Global Health Institute Program for Fellows and Scholars Project 52: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Transmission Dynamics of Residual Malaria in the Amazon) Project 53: Inter-American E-Capacity Research Training in Infectious and Chronic Diseases Project 54: Drug Discovery for Mental Disorders: Preclinical Studies of Peruvian Botanicals Project 55: Peruvian/Brazilian Amazon Center of Excellence in Malaria (Spatiotemporal Adaptation of Anopheles Darlingi in Diverse Ecological) Project 56: Fogarty Global Health Fellows Cordinating Center (The UJMT Global Consortium: Building Research Capacity through Mentored Training) Project 57: Alternative Venues tor HIV Testing with MSM and TW in Lima, Peru Project 58: Launching a Salt Substitute to Reduce Blood Pressure at the Population Level - Perú Project 59: Fogarty Global Health Fellows Coordinating Center (Metalproteinasas of the Extracellular Matrix (MMPS) in Patients) Project 60: Genetic Susceptibility to HTLV-1 Related Deseases Project 61: Kuskaya: An Interdisciplinary Training Program for Innovation in Global Health - HIV/STI Program Science Training Plan for Latin America Project 62: Fogarty Global Health Fellows Coordinating Center Project 63: Amazonian Center of Excellence in Malaria Research (Immunology of Asymtomatic Malaria and the Effects of Immunity on Plas) Project 64: Amazonian Center of Excellence in Malaria Research (Core B - Data Management) Project 65: Effects of drug loading and associated factors on the occurrence of adverse drug reactions (ADRs) during the first six months of Highly Active Antiretroviral Therapy (HAART) at a referral hospital Project 66: Planning to Establish a Regional Center of NCD Research Training in Peru Project 67: Mortality associated with the time of onset of highly active antiretroviral therapy (HAART) during the course of treatment for tuberculosis in a cohort of patients with HIV infection in Peru Project 68: Defining the patterns of antibiotic resistance among pneumococcal isolates in Peru Project 69: PARACAS Award: Need for Improvements in the Care Retention of Patients with HIV Infection in a Public Reference Hospital in Peru

The financing of these Research Projects comes from Federal Funds from the United States of America, specifically from National Institute of Health - NIH, through contracts and subcontracts with Universidad Peruana Cayetano Heredia. These financings are made in two ways: directly between the UPCH and NIH; and indirectly, through a subcontract where NIH funds to a University in the United States of America and this subcontracts the UPCH research services.

2. Accounting policies used for the preparation of the expenses statement

Accounting principles and practices used for registration of operations and preparation of expenses statement are:

(a) Accounting system-

The General management of Projects of the University prepares the expenses statement of the projects from accounting records carried in soles, in accordance with the legal provisions in force in Peru, which are converted to US dollars using the rates of exchange prevailing on the dates of the transactions.

(b) Accounting basis -

The expenses statement of the projects is prepared by the accounting department of the University on the basis of the auxiliary records of each project and the relevant documentation of expenses.

The accrual accounting basis is used for the preparation of the expenses statement. On this basis, expenses are recognized as accrued, independently of when they are paid and are recorded in the periods to which they relate

(c) Exchange rate -

For the preparation of the expenses statement of the Research Projects, costs represent monetary units in soles converted to US dollars using the exchange rates prevailing on the dates of the transactions.

(d) Recognition of expenses -

Costs related to Projects are those costs executed for activities related with the execution of the Project, in accordance with the objectives and terms of each Research Project agreement.

Disbursements are supported with legally accepted receipts, following specific procedures for the recruitment and selection of suppliers. Total amount of incurred disbursements were charged to the Projects, including the value added tax.

3. Notes to the individual expenses statements of Research Projects

Individual Expenses Statements of each of the sixty nine Research Projects for the period from January 1, 2017 to December 31 2017 financed directly or indirectly by the NIH, are as follows:

Project 1 Expenses statement

Peru Infectious Diseases Epidemiology Research Training Consortium

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Lescano, Andrés

	Project execution US\$
Direct costs	
Training	135,103
Equipment and/or supplies	85,175
Benefits to employees	73,812
Consortium	37,202
Travel expenses	31,044
Laboratory and patient care services	11,823
Consultants	2,036
Other	27,188
Total Direct costs	403,383
Total Indirect costs - Overhead	9,704
Total costs	413,087

Project Execution Period: From September 2005 to February 2020.

<u>Project General Objective</u>: The objective of this project is to train students to achieve a capacity to respond to emerging infectious diseases.

Project 2 Expenses statement

Optimizing ring screening strategy for control of taenia solium infection

Research project financed by Federal Funds from the United States of America, under a subcontract with Oregon Health & Science University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Benefits to employees	175,379
Travel expenses	53,622
Equipment and/or supplies	52,237
Laboratory and patient care services	18,441
Other	76,947
Total Direct costs	376,626
Total Indirect costs - Overhead	23,585
Total costs	400,211

Project Execution Period: From December 2013 to November 2018.

<u>Project General Objective</u>: The objective of this project is to perform a prospective clinical intervention based on the community with 5 study arms buying intervention strategies in rings versus massive treatments for the control of T. solium transmission.

Project 3

Expenses statement

<u>Peruvian/Brazilian Amazon Center of Excellence in Malaria (Epidemiology of Malaria in the Peruvian and Brazilian people)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Llanos, Elmer

	Project execution US\$
Direct costs	
Equipment and/or supplies	142,309
Benefits to employees	116,463
Travel expenses	18,721
Training	2,500
Laboratory and patient care services	591
Other	58,035
Total Direct costs	338,619
Total Indirect costs - Overhead	17,978
Total costs	356,597

Project Execution Period: From July 2010 to June 2017.

<u>Project General Objective</u>: The objective of this project is to determine the impact of asymptomatic carriers in the epidemiology and control of malaria in the Peruvian Amazon.

Project 4

Expenses statement

HIV Prevention and Care for Peruvian MSM and Transgender Women

Research project financed by Federal Funds from the United States of America, under a subcontract with The Regents of the University of California.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Cáceres, Carlos

	Project execution US\$
Direct costs	
Benefits to employees	213,809
Laboratory and patient care services	24,492
Equipment and/or supplies	15,440
Travel expenses	11,375
Consultants	1,471
Training	670
Other	53,122
Total Direct costs	320,379
Total Indirect costs - Overhead	23,385
Total costs	343,764

Project Execution Period: From February 2016 to December 2020.

<u>Project General Objective</u>: The objective of this project is to evaluate the effectiveness of Project Pride + (PO +) which is a combined prevention intervention. This intervention focuses on multiple dynamics that facilitate the transmission of HIV.

Project 5

Expenses statement

<u>Training in Infectious Diseases in Peru - Time for Capacity Strengthening in Clinical Research (Training in</u> <u>Parasitic Diseases and Central Nervous System infections)</u>

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Consortium	127,223
Training	60,705
Benefits to employees	50,005
Equipment and/or supplies	30,719
Travel expenses	8,726
Consultants	7,773
Laboratory and patient care services	3,914
Other	31,737
Total Direct costs	320,802
Total Indirect costs - Overhead	13,316
Total costs	334,118

Project Execution Period: From July 1999 to February 2021.

<u>Project General Objective</u>: The objective of this project is to develop and train students in short-term, medium-term, and long-term programs, both abroad and in Peru, providing them with training in infectious diseases.

Project 6

Expenses statement

PARACAS: Program for Advanced Research Capacities for AIDS in Peru

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gotuzzo, José

	Project execution US\$
Direct costs	
Consortium	117,307
Benefits to employees	82,271
Training	53,311
Equipment and/or supplies	10,840
Travel expenses	5,788
Laboratory and patient care services	131
Other	41,333
Total Direct costs	310,981
Total Indirect costs - Overhead	16,364
Total costs	327,345

Project Execution Period: From August 2014 to May 2019.

<u>Project General Objective</u>: The objective of this project is to nourish and consolidate a mature and increasingly stimulating environment for HIV research and training in HIV research at UPCH.

Project 7

Expenses statement

Kuskaya: An Interdisciplinary Training Program for Innovation in Global Health

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. García, Patricia

	Project execution US\$
Direct costs	
Consortium	128,534
Training	86,400
Benefits to employees	71,957
Travel expenses	3,278
Consultants	638
Equipment and/or supplies	50
Other	13,140
Total Direct costs	348,663
Total Indirect costs - Overhead	13,847
Total costs	317,844

Project Execution Period: From September 2013 to August 2018.

<u>Project General Objective:</u> The objective of this project is develop a new generation of innovative leaders in Global Health (Kuskaya Fellows), able to work collaboratively with colleagues from the North and South in interdisciplinary teams, framing problems to help find solutions through research.

Project 8

Expenses statement

Combined Albendazole and Praziguantel in Subarachnoid NCC, CCC, Lead application

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Benefits to employees	148,879
Laboratory and patient care services	46,496
Consultants	30,194
Consortium	26,739
Travel expenses	17,253
Equipment and/or supplies	16,568
Other	23,764
Total Direct costs	309,893
Total Indirect costs - Overhead	5,862
Total costs	315,755

Project Execution Period: From September 2015 to July 2020.

<u>Project General Objective</u>: The objective of this project is to demonstrate the progressive advances of Albendazole Treatment (ABZ) combined with Praziguantel (PZQ) in patients with the disease of Neurocisticercosis (NCC).

Project 9

Expenses statement

1/2-Regional Geohealth Hub Centered in Peru - Peru

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gonzales, Gustavo

	Project execution US\$
Direct costs	
Consortium	139,777
Benefits to employees	89,085
Travel expenses	18,363
Consultants	17,372
Equipment and/or supplies	2,182
Training	100
Laboratory and patient care services	62
Other	10,146
Total Direct costs	277,087
Total Indirect costs - Overhead	3,710
Total costs	280,797

Project Execution Period: From September 2015 to July 2020.

<u>Project General Objective</u>: The objective of this project is i) to conduct an intervention study of indoor air pollution and use of biomass, ii) to evaluate the relationship between outdoor air pollution and cardio respiratory disease in Lima, Peru and iii) to develop a predictive model of the impact of climate change on diarrheal diseases and vector-borne diseases (dengue, chagas and malaria).

Project 10 Expenses statement

Latin America Treatment & Innovation Network in Mental Health (LATIN-MH)

Research project financed by Federal Funds from the United States of America, under a subcontract with Fundacao Faculdade de Medicina.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Miranda, Juan

	Project execution US\$
Direct costs	
Benefits to employees	209,683
Consortium	10,376
Laboratory and patient care services	4,647
Equipment and/or supplies	2,550
Travel expenses	2,230
Other	13,168
Total Direct costs	242,654
Total Indirect costs - Overhead	
Total costs	242,654

Project Execution Period: From September 2013 to August 2018.

<u>Project General Objective</u>: The objective of this project is to collaborate to reduce the treatment gap of depression in Latin America, using treatment models of recognized effectiveness, relying on existing resources in primary care and taking advantage of the accelerated growth of technology in our country.

Project 11

Expenses statement

Tuberculosis Trials Consortium (TBTC)

Research project financed by Federal Funds from the United States of America, under a subcontract with Vanderbilt University Medical Center.

For the period from January 1, 2017 to December 31, 2017.

Researchers: Dr. Gotuzzo, Eduardo y Dr. Seas, Carlos

	Project execution US\$
Direct costs	
Benefits to employees	126,976
Travel expenses	29,196
Laboratory and patient care services	12,750
Equipment and/or supplies	11,341
Training	1,913
Other	43,121
Total Direct costs	225,297
Total Indirect costs - Overhead	14,247
Total costs	239,544

Project Execution Period: From October 2010 to September 2018.

<u>Project General Objective</u>: The objective of this project is to develop a dosage algorithm to determine dose of Levofloxacin relating to maximum efficacy with tolerance and acceptable safety.

Project 12

Expenses statement

Improving Diagnostic and Management Tolls for Neurocysticercosis (Peru -JHU TMRC Program)

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Benefits to employees	112,600
Equipment and/or supplies	28,521
Consultants	26,032
Travel expenses	23,682
Laboratory and patient care services	10,684
Training	2,350
Other	18,094
Total Direct costs	221,963
Total Indirect costs - Overhead	7,720
Total costs	229,683

Project Execution Period: From April 2017 to March 2022.

<u>Project General Objective</u>: The objective of this project is to develop three research projects and three operational units to provide a fully functional research network, as well as take advantage of the UPCH research network in Peru in this endemic disease.

Project 13 Expenses statement

Characterization of hippocampal sclerosis in individuals with calcified Neurocysticercosis

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Consortium	94,527
Laboratory and patient care services	40,375
Benefits to employees	37,187
Consultants	32,956
Travel expenses	855
Training	358
Equipment and/or supplies	228
Total Direct costs	206,486
Total Indirect costs - Overhead	8,169
Total costs	214,655

Project Execution Period: From July 2016 to June 2018.

<u>Project General Objective</u>: The objective of this project is to demonstrate the association between Neuro Cysticercosis (NCC) and Human Subjects (HS) when comparing the proportion of individuals with HS in patients with calcified NCC and in controls without NCC. As well as, determine the factors associated with HS in patients with calcified CCN, as shown by history and visual analysis of Magnetic resonance imaging (MRI) (such as number and location of lesions, duration of epilepsy, seizures, etc.).

Project 14

Expenses statement

Placental Colonization by Treponema Pallidum, Congenital Syphilis & Novel Vaccine

Research project financed by Federal Funds from the United States of America, under a subcontract with Rutgers University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Centurión, Arturo

	Project execution US\$
Direct costs	
Benefits to employees	137,100
Equipment and/or supplies	22,513
Travel expenses	18,421
Training	3,940
Laboratory and patient care services	2,616
Consultants	370
Other	11,547
Total Direct costs	196,507
Total Indirect costs - Overhead	14,991
Total costs	211,498

Project Execution Period: From August 2015 to January 2020.

<u>Project General Objective</u>: The objective of this project is to determine the impact of the adaptive immune response by antibodies against syphilis both in colonization of the placenta as well as in the clinical presentations of congenital syphilis in pregnant women.

Project 15 Expenses statement

Liver cystic echinococcosis: pre-clinical assessment of a novel, single step percutaneous treatment procedure (intracystic albendazole sulfoxide injection)

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Santivañez, Saúl

	Project execution US\$
Direct costs	
Benefits to employees	52,012
Equipment and/or supplies	41,871
Laboratory and patient care services	31,677
Travel expenses	22,866
Consultants	13,583
Consortium	9,900
Other	13,226
Total Direct costs	185,135
Total Indirect costs - Overhead	13,511
Total costs	198,646

Project Execution Period: From March 2016 to February 2021.

<u>Project General Objective</u>: The objective of this project is to evaluate a new approach of percutaneous treatment of a single step that consists in the intraquistica injection of Albendazol Sulfoxido (ABZ - SF), the active metabolite of ABZ.

Project 16 Expenses statement

Predicting Risk of Human Leptospiros by Environmental Surveillance

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Torres, Katherine

	Project execution US\$
Direct costs	
Benefits to employees	89,974
Equipment and/or supplies	40,779
Travel expenses	8,265
Laboratory and patient care services	758
Training	213
Other	48,834
Total Direct costs	188,823
Total Indirect costs - Overhead	5,355
Total costs	194,178

Project Execution Period: From June 2013 to May 2018.

<u>Project General Objective</u>: The objective of this project is to develop and validate new tools and approaches to reduce the impact of leptospirosis on human health.

Project 17

Expenses statement

Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community

Research project financed by Federal Funds from the United States of America, under a subcontract with Johns Hopkins University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Zimic, Mirko

	Project execution US\$
Direct costs	
Benefits to employees	109,943
Equipment and/or supplies	39,937
Travel expenses	2,496
Laboratory and patient care services	1,207
Consultants	734
Other	19,144
Total Direct costs	173,461
Total Indirect costs - Overhead	12,403
Total costs	185,864

Project Execution Period: From June 2015 to May 2018.

<u>Project General Objective</u>: The objective of this project is to characterize the epidemiology of Norovirus (NV) and Sapovirus (SV) in Peruvian children. As well as, evaluate the people who acquired protective immunity to NV in a setting of frequent exposure.

Project 18

Expenses statement

Use of bisphosphonates to reduce the calcification process in animal models of cysticercosis

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Bustos, Javier

	Project execution US\$
Direct costs	
Benefits to employees	77,989
Equipment and/or supplies	15,126
Consultants	13,496
Laboratory and patient care services	3,355
Travel expenses	3,111
Training	250
Other	26,671
Total Direct costs	139,998
Total Indirect costs - Overhead	10,822
Total costs	150,820

Project Execution Period: From March 2015 to February 2020.

<u>Project General Objective</u>: The objective of this project is to evaluate whether Bisphosphonates decrease the likelihood and degree of residual calcification from the degeneration of the muscular and cerebral cyst of brain degeneration and cysts in animal models.

Project 19

Expenses statement

Strengthening and consolidating Resources for VIH Prevention in the Peruvian Military

Research project financed by Federal Funds from the United States of America, under a subcontract with Navsup Fleet Logistics Support Center.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Cáceres, Carlos

	Project execution US\$
Direct costs	
Benefits to employees	110,974
Travel expenses	7,661
Equipment and/or supplies	2,672
Training	2,099
Consultants	1,839
Laboratory and patient care services	247
Other	7,121
Total Direct costs	132,613
Total Indirect costs - Overhead	7,380
Total costs	139,993

Project Execution Period: From March 2015 to February 2019.

<u>Project General Objective</u>: The objective of this project is to create a program focused on improving access to HIV prevention in military population in mayor risk of four regions of the country during its first year (Lima-Callao, Piura, Iquitos and Arequipa), by strengthening existing resources through the administration of Comité de Prevención y Control de VIH/SIDA (COPRECOS -PERU).

Project 20 Expenses statement

Translational Research Development for Endemic Infectious Diseases of Amazonia

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gamboa, Dionicia

	Project execution US\$
Direct costs	
Training	68,391
Travel expenses	23,946
Benefits to employees	17,993
Equipment and/or supplies	7,500
Other	14,711
Total Direct costs	132,541
Total Indirect costs - Overhead	49
Total costs	132,590

Project Execution Period: From May 2016 to February 2021.

<u>Project General Objective</u>: The goal of this new project infectious disease research training program, with focus on training candidates from Iquitos (Universidad Nacional de la Amazonia Peruana). This research training program, explicitly focuses on augmenting and sustaining research capacity in emerging and major endemic infectious diseases in Peru, particularly those found in the Peruvian Amazon. This training program will be particularly focused on infectious diseases that are associated with substantial morbidity and mortality in the Peruvian Amazon.

Project 21 Expenses statement

Impact of Fascioliasis among Children in the Peruvian Highlands

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Cabada, Miguel

	Project execution US\$
Direct costs	
Benefits to employees	90,385
Equipment and/or supplies	24,384
Travel expenses	7,317
Training	695
Laboratory and patient care services	180
Other	705
Total Direct costs	123,666
Total Indirect costs - Overhead	7,615
Total costs	131,281

Project Execution Period: From February 2013 to January 2018.

<u>Project General Objective</u>: The objective of this project is to define: i) the epidemiology of clinical and subclinical Fascioliasis in an endemic area in Cusco, Peru, ii) the impact of subclinical Fascioliasis on infant nutrition and anemia, and iii) the mechanisms involved in the pathogenesis of anemia and malnutrition associated with Fascioliasis

Project 22 Expenses statement

Implementation of foot thermometry and SMS to prevent diabetic foot ulcer

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Miranda, Juan

	Project execution US\$
Direct costs	
Consortium	86,815
Benefits to employees	33,291
Laboratory and patient care services	4,491
Travel expenses	612
Equipment and/or supplies	88
Other	523
Total Direct costs	125,820
Total Indirect costs - Overhead	47
Total costs	125,867

Project Execution Period: From September 2014 to September 2017.

<u>Project General Objective</u>: The objective of this project is to determine the usefulness of text messaging to remind patients to take measurements and evaluate the impact on the outcome.

Project 23

Expenses statement

TOD@S (Transforming Ourselves through Dialogue, Organizing, and Service): An Anti-Violence Program for Transgender people in Peru

Research project financed by Federal Funds from the United States of America, under a subcontract with Fenway Community Health Center.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Silva, Alfonso

	Project execution US\$
Direct costs	
Benefits to employees	64,173
Consultants	27,704
Travel expenses	14,077
Laboratory and patient care services	3,188
Equipment and/or supplies	436
Other	7,458
Total Direct costs	117,036
Total Indirect costs - Overhead	7,871
Total costs	124,907

Project Execution Period: From June 2015 to June 2019.

<u>Project General Objective</u>: The objective of this project is to improve the safety and well-being of transgender people affected by violence, harassment and violations of human rights and in Peru through the creation of a working group.

Project 24

Expenses statement

International Prospective Observational Cohort Study of Sika in Infants and Pregnancy Zika in Infants and Pregnancy Study (ZIP staudy)

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Alabama.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Ochoa, Theresa

	Project execution US\$
Direct costs	
Consortium	47,307
Benefits to employees	38,244
Equipment and/or supplies	18,999
Travel expenses	5,016
Training	1,129
Other	7,424
Total Direct costs	118,119
Total Indirect costs - Overhead	3,949
Total costs	122,068

Project Execution Period: From June 2017 to November 2019.

<u>Project General Objective</u>: The objective of this project is to compare the incidence of congenital malformations and adverse fetal consequences (such as microcephaly, death of the fetus, neonatal death, malformations of the Central Nervous System (CNS), dropsy and ocular abnormalities) in fetuses and infants of: i) women who have been infected with the Zika Virus, ii) women who have developed symptoms of an infection with ZIKV; and iii) women who have not developed symptoms.

Project 25 Expenses statement

Disrupting Vector-Borne Desease Transmission in Complex Urban Environments

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Pennsylvania.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Naquira, Cesar

	Project execution US\$
Direct costs	
Benefits to employees	65,249
Consultants	11,454
Travel expenses	5,456
Training	5,383
Equipment and/or supplies	3,122
Laboratory and patient care services	9
Other	15,014
Total Direct costs	105,687
Total Indirect costs – Overhead	12,089
Total costs	117,776

Project Execution Period: From June 2013 to May 2018.

<u>Project General Objective</u>: The objective of this project is to improve vector transmission models by the development of realistic methods to make inferences about spatial processes.

Project 26

Expenses statement

Peruvian/Brazilian Amazon Center of Excellence in Malaria (Core B Data Management - ICEMR)

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Vinetz, Joseph

	Project execution US\$
Direct costs	
Benefits to employees	97,989
Equipment and/or supplies	3,983
Travel expenses	3,804
Other	1,183
Total Direct costs	106,959
Total Indirect costs - Overhead	2,140
Total costs	109,099

Project Execution Period: From July 2010 to June 2017.

<u>Project General Objective</u>: The objective of this project is to guide the design of the study, ensure the safe collection of the necessary data in the appropriate format and carry out a statistical analysis of data in all the research activities in the International Center of Excellence in Malaria Research (ICEMR) Peru-Brazil program.

Project 27

Expenses statement

Improving participation in vector controls campaigns through behavioral economics

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Pennsylvania.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Naquira, Cesar

	Project execution US\$
Direct costs	
Benefits to employees	63,109
Consultants	15,271
Travel expenses	2,542
Equipment and/or supplies	850
Other	8,862
Total Direct costs	90,634
Total Indirect costs - Overhead	9,081
Total costs	99,715

Project Execution Period: From June 2014 to May 2019.

<u>Project General Objective</u>: The objective of this project is to carry out randomized field work with three interventions to increase participation in vector control campaigns carried out by the Ministry of Health (MINSA) in Arequipa, Peru.

Project 28

Expenses statement

Lactoferrin for Prevention of Sepsis in Infants

Research project financed by Federal Funds from the United States of America, under a subcontract with the University of Texas Health Science Center at Houston.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Ochoa, Theresa

	Project execution US\$
Direct costs	
Equipment and/or supplies	9,238
Benefits to employees	6,864
Consultants	6,484
Travel expenses	1,154
Training	947
Other	59,266
Total Direct costs	83,953
Total Indirect costs - Overhead	2,362
Total costs	86,315

Project Execution Period: From April 2011 to March 2017.

<u>Project General Objective</u>: The objective of this project is to determine whether Lactorerrin administered orally daily as a nutritional supplement to low-income children will improve their health, simulating its protective role in breast milk.

Project 29

Expenses statement

Evaluating Corraling nad the Effect of Dung Beetles on Transmission and Control of Cysticercosis

Research project financed by Federal Funds from the United States of America, under a subcontract with Oregon Health & Science University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. González, Armando

	Project execution US\$
Direct costs	
Equipment and/or supplies	27,314
Benefits to employees	18,106
Laboratory and patient care services	11,535
Consultants	4,721
Travel expenses	1,377
Other	11,135
Total Direct costs	74,188
Total Indirect costs - Overhead	6,082
Total costs	80,270

Project Execution Period: From July 2015 to June 2017.

<u>Project General Objective</u>: The objective of this project is to evaluate the effect of corrals and coprophagous beetles in the transmission of Porcine Cysticercosis using a longitudinal study that evaluates the incidence in three groups of pigs, freely bred, raised in pen and raised in pens with nets that prevent the entrance of beetles.

Project 30 Expenses statement

Infectious Diseases Training Program in Bolivia: South - South Training with Peru

Research project financed by Federal Funds from the United States of America, under a subcontract with Johns Hopkins University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Benefits to employees	24,875
Equipment and/or supplies	9,640
Training	5,714
Travel expenses	1,664
Other	21,201
Total Direct costs	63,094
Total Indirect costs - Overhead	8,603
Total costs	71,697

Project Execution Period: From May 2015 to January 2018.

<u>Project General Objective</u>: The objective of this project is to develop and build a long-term sustainable training program in tropical infectious diseases in Bolivia.

Project 31 Expenses statement

Prevalence and Incidence of Neonatal HSV (Herpes Simplex) in Pre-term Infants

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Alabama.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Cárcamo, Cesar

	Project execution US\$
Direct costs	
Benefits to employees	63,707
Equipment and/or supplies	5,171
Travel expenses	86
Other	51
Total Direct costs	69,015
Total Indirect costs - Overhead	<u>-</u>
Total costs	69,015

Project Execution Period: From August 2016 to March 2021.

<u>Project General Objective</u>: The objective of this project is to estimate the incidence of neonatal Herpes by combining two components: i) to determine the prevalence of Herpes simplex virus (HSV) infection confirmed by Polymerase Chain Reaction (PCR) in neonates with the diagnosis of suspected Sepsis or Meningitis (SSM) and ii) to estimate the incidence of SSM in a cohort prospective of newborns.

Project 32 Expenses statement

Assesing how Relationships between MSM influence HIV Prevention Strategies

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, Los Angeles.

For the period from January 1, 2017 to December 31, 2017.

Investigadores: Dra. Konda, Kelika y Dr. Cáceres, Carlos

	Project execution US\$
Direct costs	
Benefits to employees	25,517
Laboratory and patient care services	8,857
Travel expenses	3,026
Consultants	2,525
Equipment and/or supplies	2,121
Other	20,125
Total Direct costs	62,171
Total Indirect costs - Overhead	3,944
Total costs	66,115

Project Execution Period: From January 2015 to June 2018.

Project General Objective: The objective of this project is: i) to explore the nature of sexual relationships between MSM and generate a theory about how relationships between MSM influence the use and acceptance of existing and new human immunodeficiency virus (HIV) / sexually transmitted infections (STI) prevention strategies, through qualitative data, ii) to examine the influence of Men who have sex with men (MSM) sexual relations in their sexual risk behavior and in their acceptance of existing and new HIV / STI prevention strategies, including information on sexual dyads, through a quantitative survey, and iii) developing a multicomponent intervention for MSM using small groups and Couples Voluntary Counseling and Testing (CVCT) with a focus on the relationship status of individuals based on the results of objectives i) and ii).

Project 33 Expenses statement

Runachay: Information and Communication Technologies for Global Health Research

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Blas, Magaly

	Project execution US\$
Direct costs	
Benefits to employees	47,181
Training	4,000
Equipment and/or supplies	456
Travel expenses	16
Other	6,978
Total Direct costs	58,631
Total Indirect costs - Overhead	3,961
Total costs	62,592

Project Execution Period: From May 2014 to April 2018.

<u>Project General Objective</u>: The objective of this project is to develop an electronic platform to offer distance learning opportunities in Spanish in the short and medium term in research and in the use of Information and Communications Technologies (ICT) for research in Global Health.

Project 34

Expenses statement

Combined Albendazole Plus Praziguantel in Subarachnoid NCC, DCC Application

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Lescano, Andrés

	Project execution US\$
Direct costs	
Benefits to employees	22,910
Consortium	14,515
Travel expenses	5,720
Consultants	1,916
Equipment and/or supplies	1,620
Laboratory and patient care services	366
Other	5,890
Total Direct costs	52,937
Total Indirect costs – Overhead	6,005
Total costs	58,942

Project Execution Period: From September 2015 to July 2020.

<u>Project General Objective</u>: The objective of this project is to establish a Data Coordination Center (DCC) for the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS) clinical trial application entitled "A Randomized Trial of Combined Albendazole Plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns". In the study mentioned above five years, a total of 164 subjects, the subjects will be enrolled in a randomized, double-blind clinical trial with 12 months of follow-up each.

Project 35 Expenses statement

Syphilis: Translating technology to understand a neglected epidemic

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Cáceres, Carlos

	Project execution US\$
Direct costs	
Consortium	29,065
Benefits to employees	19,743
Consultants	1,000
Laboratory and patient care services	629
Equipment and/or supplies	548
Other	2,433
Total Direct costs	53,418
Total Indirect costs - Overhead	3,876
Total costs	57,294

Project Execution Period: From August 2012 to July 2017.

<u>Project General Objective</u>: The objective of this project is i) to recruit a group of 400 Men who have sex with men Transgender(MSM TG) at high risk for syphilis, for a follow-up of 24 months, ii) to evaluate the persistent reactivity to syphilis by characterizing the host, pathogenic factors and environmental factors, and the comparison of the evolution of immunological parameters and iii) to identify the key strategies to improve the current management of syphilis and develop a R01 proposal to evaluate its effectiveness, based on the results of the study in the previous points.

Project 36

Expenses statement

Human Inmmune Signatures of Dengue Virus and Mycobacterium Tuberculosis exposure in Infection, Disease and Vaccionation

Research project financed by Federal Funds from the United States of America, under a subcontract with La Jolla Institute for Allergy and Immunology (LIAI).

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gilman, Robert

	Project execution US\$
Direct costs	
Laboratory and patient care services	21,446
Benefits to employees	20,657
Consortium	4,034
Equipment and/or supplies	3,637
Consultants	1,500
Travel expenses	1,238
Other	1,106
Total Direct costs	53,618
Total Indirect costs - Overhead	
Total costs	53,618

Project Execution Period: From June 2015 to May 2018.

<u>Project General Objective</u>: The objective of this project is to characterize immune signatures (IMS) in individuals associated with four different states of Mycobacterium tuberculosis (MTB) exposure, those who have i) a contained latent infection, ii) an uncontrollable infection characterized as active disease, iii) received Bacillus de Calmette and Guérin, better known by its acronym BCG, is the tuberculosis vaccine or experimental vaccination; and iv) non-exposed individuals who were not vaccinated and without evidence of past or present infection.

Project 37 Expenses statement

Addressing the Global Burden of Leptospirosis in Two Endemic Countries

Research project financed by Federal Funds from the United States of America, under a subcontract with The Regents of The University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Torres, Katherine

	Project execution US\$
Direct costs	
Benefits to employees	38,377
Travel expenses	4,780
Laboratory and patient care services	2,249
Equipment and/or supplies	1,789
Other	193
Total Direct costs	47,388
Total Indirect costs - Overhead	-
Total costs	47,388

Project Execution Period: From September 2015 to February 2020.

<u>Project General Objective</u>: The objective of this project is i) to develop well-characterized collections of serum and urine from patients with definitively diagnosed Leptospirosis; and ii) to identify the most important medical Leptospires that cause disease in geographically distinct areas (quantitatively and those associated with extreme spectra of disease, mild to severe).

Project 38

Expenses statement

<u>Peruvian/Brazilian Amazon Center of Excellence in Malaria (Interaction between Human-Plasmodium</u> <u>Mosquito in the Transmission of Malaria)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Llanos, Elmer

	Project execution US\$
Direct costs	
Benefits to employees	28,779
Laboratory and patient care services	3,125
Equipment and/or supplies	1,706
Travel expenses	387
Other	8,318
Total Direct costs	42,315
Total Indirect costs - Overhead	2,467
Total costs	44,782

Project Execution Period: From July 2010 to June 2017.

<u>Project General Objective</u>: The objective of this project is i) to determine the contributions and associations between the human humoral response, the response of human Cytokines and the quality of the Plasmodium Vivax gametocytes with the transmission of the parasite to the mosquito Anopheles Darlingi, ii) to evaluate the susceptibility of mosquitoes, potential malaria vectors Anopheles Darlingi colonized and non-Anopheles for infection by Plasmodium Vivax and iii) to determine mechanisms of blocking activity of transmission in patients with naturally acquired transmission blocking blocking antibodies.

Project 39

Expenses statement

<u>Peruvian/Brazilian Amazon Center of Excellence in Malaria (Shared Laboratory resource - Core C - ICEMR)</u> Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gamboa, Dionicia

	Project execution US\$
Direct costs	
Equipment and/or supplies	21,742
Benefits to employees	16,099
Laboratory and patient care services	1,581
Travel expenses	1,103
Other	58
Total Direct costs	40,583
Total Indirect costs - Overhead	2,871
Total costs	43,454

Project Execution Period: From July 2010 to June 2017.

<u>Project General Objective</u>: The objective of this project is to establish and manage a common platform of research facilities in the University that guarantees the success of this Center at an international level. This core will provide a technological platform with a multi-user conception. In this way, the partners of the International Center of Excellence in Malaria Research will have centralized access to state-of-the-art technology in a single environment.

Project 40 Expenses statement

CCASAnet: Caribbean, Central and South America Network

Research project financed by Federal Funds from the United States of America, under a subcontract with Vanderbilt University Medical Center.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gotuzzo, José

	Project execution US\$
Direct costs	
Benefits to employees	34,983
Equipment and/or supplies	685
Other	1,453
Total Direct costs	37,121
Total Indirect costs - Overhead	2,401
Total costs	39,522

Project Execution Period: From July 2016 to June 2021.

<u>Project General Objective</u>: The objective of this project is to investigate the changing epidemiology of human immunodeficiency virus (HIV) / acquired immunodeficiency syndrome (AIDS) in the context of wider use and availability of antiretroviral therapy, differences in HIV care and treatment programs, an aging HIV population and an increasing number of children exposed but not infected with HIV.

Project 41

Expenses statement

Oxfendazole as a Broad Spectrum Deworming Medicine in Humans: Phase II Efficacy Study in Geohelminths Research project financed by Federal Funds from the United States of America, under a subcontract with Johns Hopkins University.

For the period from January 1, 2017 to December 31, 2017.

Investigadora: Dr. García, Héctor

	Project execution US\$
Direct costs	
Benefits to employees	19,471
Consultants	14,000
Equipment and/or supplies	361
Total Direct costs	33,832
Total Indirect costs - Overhead	1,386
Total costs	35,218

Project Execution Period: From July 2016 to December 2017.

<u>Project General Objective</u>: The objective of this project is to demonstrate the efficacy of Oxfendazole (OXF) in the treatment of Trichuris trichiura, based on the preclinical data of the OXF as a method of deworming.

Project 42

Expenses statement

ICTUS: Interdisciplanary Cerebrovascular Diseases Training Program in South America

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Washington.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. García, Héctor

	Project execution US\$
Direct costs	
Benefits to employees	23,243
Laboratory and patient care services	6,197
Equipment and/or supplies	2,901
Total Direct costs	32,341
Total Indirect costs - Overhead	1,751
Total costs	34,092

Project Execution Period: From June 2016 to May 2018.

<u>Project General Objective</u>: The objective of this project is to reduce mortality in cerebrovascular diseases in Peru.

Project 43 Expenses statement

Predictors of Cardiomypathy Progression in a Chagas Disease Cohort in Bolivia

Research project financed by Federal Funds from the United States of America, under a subcontract with Johns Hopkins University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Verastegui, Manuela

	Project execution US\$
Direct costs	
Benefits to employees	18,439
Equipment and/or supplies	11,858
Travel expenses	178
Other	995
Total Direct costs	31,470
Total Indirect costs - Overhead	2,223
Total costs	33,693

Project Execution Period: From February 2014 to January 2018.

<u>Project General Objective</u>: The objective of this project is to determine whether the treatment of biomarkers used for the early detection of Chagas disease to the heart may reflect early changes in cardiac structure and function, substances such as natriuretic type Bpeptide released in response to heart disease or a substance such as factor of transforming growth, involved in cardiac pathogenesis at the cellular level.

Project 44

Expenses statement

CHAKA: Strengthening Research Support Structures in the Andean Region

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Chan, Michelle

	Project execution US\$
Direct costs	
Benefits to employees	21,523
Training	6,930
Travel expenses	1,074
Other	3,165
Total Direct costs	32,692
Total Indirect costs - Overhead	408
Total costs	33,100

Project Execution Period: From May 2016 to April 2021.

<u>Project General Objective</u>: The objective of this project is to develop a generation of qualified managers in the management of research projects at the Universidad Peruana Cayetano Heredia, and catalyze a career in the administration of research, which will help develop an enabling environment and systems for health research.

Project 45

Expenses statement

<u>Multidisciplinary Training Program on Neuropsychiatry and Behavioral Disorders in First Nations (NEUFIN)</u> Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gallo, Carla

	Project execution US\$
Direct costs	
Travel expenses	14,883
Training	11,460
Benefits to employees	2,977
Equipment and/or supplies	125
Other	51
Total Direct costs	29,496
Total Indirect costs - Overhead	2,636
Total costs	32,132

Project Execution Period: From March 2015 to February 2020.

<u>Project General Objective</u>: The objective of this project is to develop the capacity for sustainable research in Bolivia, Paraguay, Peru and Argentina. A five-year joint training program will be developed with researchers from those 4 countries and the United States in the areas of epidemiology, genetics and neuroimaging for the study of Major psychiatric disorders in native populations of South America.

Project 46

Expenses statement

Peruvian/Brazilian Amazon Center of Excellence in Malaria (Core A Training - ICEMR)

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Vinetz, Joseph

	Project execution US\$
Direct costs	
Benefits to employees	26,054
Travel expenses	3,247
Training	800
Laboratory and patient care services	160
Equipment and/or supplies	11
Other	
Total Direct costs	30,485
Total Indirect costs - Overhead	50
Total costs	30,535

Project Execution Period: From July 2010 to June 2017.

<u>Project General Objective</u>: The objective of this project is to provide the infrastructure to ensure the scientific success of the International Center of Excellence in Malaria Research (5 integrated scientific projects) with data management and shared pools of laboratory resources.

Project 47

Expenses statement

Inter-American Training for Innovations in Emerging Infectious Diseases

Research project financed by Federal Funds from the United States of America, under a subcontract with Tulane University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Zimic, Mirko

	Project execution US\$
Direct costs	
Benefits to employees	21,048
Equipment and/or supplies	3,449
Travel expenses	846
Other	4,690
Total Direct costs	30,033
Total Indirect costs - Overhead	2
Total costs	30,035

Project Execution Period: From September 2016 to August 2018.

<u>Project General Objective</u>: The objective of this project is to build teams of interdisciplinary researchers who can creatively and sustainably address the problems of emerging infectious diseases by developing cost-effective tools that can be applied effectively in Latin America and other parts of the developing world.

Project 48

Expenses statement

2/2 - Regional Geohealth Hub Centered in Peru - US

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Emory.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gonzales, Gustavo

	Project execution US\$
Direct costs	
Consultants	8,000
Travel expenses	5,746
Training	2,000
Equipment and/or supplies	154
Other	10,583
Total Direct costs	26,483
Total Indirect costs - Overhead	26
Total costs	26,509

Project Execution Period: From September 2015 to July 2020.

<u>Project General Objective</u>: The objective of this project is to develop and validate new tools and approaches to reduce the impact of leptospirosis on human health.

Project 49

Expenses statement

<u>Structural Behavioral HIV Prevention for Male Sex Workers in Peru - Planning a Skil-Building Program to</u> <u>Prevent HIV in Male an Transgender)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, Los Angeles.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. García, Patricia

	Project execution US\$
Direct costs	
Benefits to employees	8,447
Consultants	4,454
Travel expenses	841
Equipment and/or supplies	367
Other	10,860
Total Direct costs	24,969
Total Indirect costs - Overhead	4
Total costs	24,973

Project Execution Period: From August 2014 to June 2018.

<u>Project General Objective</u>: The objective of this project is to carry out planning to develop and evaluate a Capacity Building Program (CBP) to prevent human immunodeficiency virus (HIV) / Sexually Transmitted Infections (STIs) among male and trans sex workers (MTSW) in Lima.

Project 50

Expenses statement

<u>Center for HIV Identification, Prevention and Treatment Services (CHIPTS) - Link your life: Linkage and</u> <u>Retention in Care for PLH</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, Los Angeles.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Egoavil, Miguel

	Project execution US\$
Direct costs	
Benefits to employees	22,909
Laboratory and patient care services	439
Equipment and/or supplies	181
Travel expenses	167
Other	141
Total Direct costs	23,837
Total Indirect costs - Overhead	1,122
Total costs	24,959

Project Execution Period: From March 2017 to January 2018.

<u>Project General Objective</u>: The objective of this project is to develop a description of the linkage process of newly diagnosed People living with HIV (PLHIV) from key populations in Lima, Peru.

Project 51 Expenses statement

University of California Global Health Institute Program for Fellows and Scholars

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Francisco.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Lescano, Andrés

	Project execution US\$
Direct costs	
Training	12,379
Equipment and/or supplies	4,336
Benefits to employees	2,637
Travel expenses	505
Laboratory and patient care services	231
Other	3,952
Total Direct costs	24,040
Total Indirect costs - Overhead	383
Total costs	24,423

Project Execution Period: From April 2012 to June 2022.

<u>Project General Objective</u>: The objective of this project is to conduct a program through the consortium of four universities in California, USA, funded by the National Institutes of Health of the USA with the objective of providing mentored research internships during 12 months in Peru in favor of North American or Peruvian researchers.

Project 52

Expenses statement

<u>Peruvian/Brazilian Amazon Center of Excellence in Malaria (Transmission Dynamics of Residual Malaria in</u> <u>the Amazon)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gamboa, Dionicia

	Project execution US\$
Direct costs	
Benefits to employees	16,827
Equipment and/or supplies	181
Travel expenses	15
Other	32
Total Direct costs	17,055
Total Indirect costs - Overhead	3,693
Total costs	20,748

Project Execution Period: From July 2017 to March 2024.

<u>Project General Objective</u>: The objective of this project is i) to prepare all documents (ethical and administrative) to collect samples (census, Global Positioning System (GPS) and sample collection) in the selected communities in this International Center of Excellence in Malaria Research (ICEMR) (districts of Santa Emilia, Mazan and San Juan, including Cahuide and Lupuna) and ii) to finalize all genotyping analyzes of the samples collected in ICEMR 1 (3-year cohort of around 3,000 subjects).

Project 53

Expenses statement

Inter-American E-Capacity Research Training in Infectious and Chronic Diseases

Research project financed by Federal Funds from the United States of America, under a subcontract with Tulane University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Zimic, Mirko

	Project execution US\$
Direct costs	
Equipment and/or supplies	9,140
Benefits to employees	1,760
Other	3,297
Total Direct costs	14,197
Total Indirect costs - Overhead	4,090
Total costs	18,287

Project Execution Period: From May 2015 to August 2018.

<u>Project General Objective</u>: The objective of this project is to carry out pilot e-Learning capacity building projects using examples of research training in collaborative projects.

Project 54

Expenses statement

Drug Discovery for Mental Disorders: Preclinical Studies of Peruvian Botanicals

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Vaisberg, Abraham

	Project execution US\$
Direct costs	
Equipment and/or supplies	5,760
Benefits to employees	4,458
Travel expenses	723
Other	7,312
Total Direct costs	18,253
Total Indirect costs - Overhead	25
Total costs	18,278

Project Execution Period: From May 2013 to April 2017.

<u>Project General Objective</u>: The objective of this project is to discover new pharmaceutical products of the Peruvian flora traditionally used for the treatment of mental disorders.

Project 55

Expenses statement

<u>Peruvian/Brazilian Amazon Center of Excellence in Malaria (Spatiotemporal Adaptation of Anopheles</u> <u>Darlingi in Diverse Ecological)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gamboa, Dionicia

	Project execution US\$
Direct costs	
Benefits to employees	10,507
Training	5,000
Total Direct costs	15,507
Total Indirect costs - Overhead	1,700
Total costs	17,207

Project Execution Period: From July 2017 to March 2024.

<u>Project General Objective</u>: The objective of this project is to study the ecological characteristics of Anopheles Darlingi, the most important vector of Malaria in the Amazon, which contributes to the maintenance of Malaria despite the implementation of different control strategies.

Project 56

Expenses statement

<u>Fogarty Global Health Fellows Cordinating Center (The UJMT Global Consortium: Building Research</u> <u>Capacity through Mentored Training)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of North Carolina at Chapel Hill.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Zimic, Mirko

	Project execution US\$
Direct costs	
Training	10,179
Equipment and/or supplies	1,325
Benefits to employees	787
Other	3,823
Total Direct costs	16,114
Total Indirect costs - Overhead	651
Total costs	16,765

Project Execution Period: From July 2017 to June 2018.

<u>Project General Objective</u>: The objective of this project is to train young students in clinical research.

Project 57 Expenses statement

Alternative Venues tor HIV Testing with MSM and TW in lima, Peru

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, Los Angeles.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Cáceres, Carlos y Dra. Konda, Kelika

	Project execution US\$
Direct costs	
Laboratory and patient care services	8,944
Benefits to employees	4,402
Travel expenses	700
Other	1,808
Total Direct costs	15,854
Total Indirect costs - Overhead	889
Total costs	16,743

Project Execution Period: From March 2015 to February 2017.

<u>Project General Objective</u>: The objective of this project is to evaluate the need for interventions that improve the retention in the care of People living with HIV in Hospital Nacional Cayetano Heredia.

Project 58

Expenses statement

$\underline{Launching\ a\ Salt\ Substitute\ to\ Reduce\ Blood\ Pressure\ at\ the\ Population\ Level\ -\ Per\acute{u}$

Research project financed by Federal Funds from the United States of America, under a subcontract with Johns Hopkins University.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Miranda, Juan

	Project execution US\$
Direct costs	
Laboratory and patient care services	9,183
Benefits to employees	294
Other	1,242
Total Direct costs	10,719
Total Indirect costs - Overhead	1,352
Total costs	12,071

Project Execution Period: From May 2012 to March 2018.

<u>Project General Objective</u>: The objective of this project is to implement a salt replacement intervention in the population to cope with high blood pressure. The data generated and the lessons learned from this study will provide a solid platform to address possible interventions applicable to other similar low and middle income environments.

Project 59

Expenses statement

<u>Fogarty Global Health Fellows Coordinating Center (Metalproteinasas of the Extracellular Matrix (MMPS) in</u> <u>Patients)</u>

Research project financed by Federal Funds from the United States of America, under a subcontract with University of North Carolina at Chapel Hill.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Ugarte, Cesar

	Project execution US\$
Direct costs	
Equipment and/or supplies	6,481
Other	624
Total Direct costs	7,105
Total Indirect costs - Overhead	1,846
Total costs	8,951

Project Execution Period: From October 2013 to November 2017.

<u>Project General Objective:</u> The objective of this project is to define the profile of Metalproteinasas of the Extracellular Matrix (MMPs), Procollagen III N-Terminal Propeptide (PIIIN) and its inhibitors (TIMPs), plasma of patients recently diagnosed with Tuberculosis, Tuberculosis / Diabetes Mellitus, Tuberculosis / human immunodeficiency virus and healthy controls.

Project 60 Expenses statement

Genetic Susceptibility to HTLV-1 Related Deseases

Research project financed by Federal Funds from the United States of America, under a subcontract with University of Miami.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gotuzzo, José

	Project execution US\$
Direct costs	
Benefits to employees	3,628
Equipment and/or supplies	2,843
Total Direct costs	6,471
Total Indirect costs - Overhead	20
Total costs	6,491

Project Execution Period: From April 2017 to April 2018.

<u>Project General Objective</u>: The objective of this project is to determine the possible genetic link between samples received from patients affected with HTLV-1-associated myelopathy / tropical spastic paraparesis (TSP) in the areas monitored in Peru.

Project 61

Expenses statement

Kuskaya: An Interdisciplinary Training Program for Innovation in Global Health - HIV/STI Program Science Training Plan for Latin America

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. García, Patricia

	Project execution US\$
Direct costs	
Travel expenses	4,943
Training	1,488
Total Direct costs	6,431
Total Indirect costs - Overhead	
Total costs	6,431

Project Execution Period: From September 2013 to August 2018.

<u>Project General Objective</u>: The objective of this project is to implement a training plan in Sciences of the Programs for human immunodeficiency virus (HIV) / Sexually Transmitted Infections (STIs) for Latin American researchers, professionals and public health managers.

Project 62

Expenses statement

Fogarty Global Health Fellows Coordinating Center

Research project financed by Federal Funds from the United States of America, under a subcontract with University of North Carolina at Chapel Hill.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Zimic, Mirko

	Project execution US\$
Direct costs	
Equipment and/or supplies	2,921
Benefits to employees	1,653
Travel expenses	48
Other	538
Total Direct costs Total Indirect costs - Overhead	5,160
Total costs	5,160

<u>Project Execution Period</u>: From August 2014 to date. There is a consent of the Mentor in the United States of the Program to continue executing expenses after the termination date according to subcontract (July 2016) in order to meet the objectives of the project. To date of our review, la Management estimated the project will be completed during the last quarter of the year 2018.

<u>Project General Objective</u>: The objective of this project is to promote research capacity in low-income countries and in particular to develop the next generation of clinical researchers, strengthen international health research capacity and foster global health collaboration.

Project 63

Expenses statement

<u>Amazonian Center of Excellence in Malaria Research (Immunology of Asymtomatic Malaria and the Effects</u> of Immunity on Plas)

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gamboa, Dionicia

	Project execution US\$
Direct costs	
Benefits to employees	3,578
Total Direct costs	3,578
Total Indirect costs - Overhead	1,473
Total costs	5,051

Project Execution Period: From July 2017 to March 2024.

<u>Project General Objective</u>: The objective of this project is i) to prepare all documents to collect samples of asymptomatic and symptomatic Malaria and health controls and ii) to conduct training trials to compare innate immune responses in asymptomatic and symptomatic Malaria.

Project 64

Expenses statement

Amazonian Center of Excellence in Malaria Research (Core B - Data Management)

Research project financed by Federal Funds from the United States of America, under a subcontract with University of California, San Diego.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Gamboa, Dionicia

	Project execution US\$
Direct costs	
Benefits to employees	3,149
Equipment and/or supplies	94
Travel expenses	5
Total Direct costs	3,248
Total Indirect costs - Overhead	456
Total costs	3,704

Project Execution Period: From July 2017 to March 2024.

<u>Project General Objective:</u> The objective of this project is to provide comprehensive data management and statistical support for all projects of the International Center of excellence in malaria research (ICEMR) Amazonia Program. Its functions include: study guide design; develop study protocols and metadata; guarantee the collection, management and exchange of adequate and safe data; generate simple tabulations routinely and as requested by project leaders; provide training as needed; and help with statistical analysis.

Project 65 Expenses statement

Effects of drug loading and associated factors on the occurrence of adverse drug reactions (ADRs) during the first six months of Highly Active Antiretroviral Therapy (HAART) at a referral hospital

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH, through the PARACAS Project.

For the period from January 1, 2017 to December 31, 2017.

Investigadores: Dra. González, Elsa y Dr. Legua, Pedro

	Project execution US\$
Direct costs	
Benefits to employees	2,471
Laboratory and patient care services	196
Travel expenses	28
Other	51
Total Direct costs	2,746
Total Indirect costs - Overhead	
Total costs	2,746

Project Execution Period: From August 2016 to May 2019.

<u>Project General Objective</u>: The objective of this project is to evaluate, in patients who initiate HAART, the effect of drug loading, alcoholism, drug use, hepatitis B, hepatitis C, chronic kidney disease and depression as risk factors for the appearance of ADR during the first 6 months of treatment.

Project 66 Expenses statement

Planning to Establish a Regional Center of NCD Research Training in Peru

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Miranda, Juan

	Project execution US\$
Direct costs	
Benefits to employees	2,483
Total Direct costs	2,483
Total Indirect costs - Overhead	30
Total costs	2,513

Project Execution Period: From September 2017 to September 2018.

<u>Project General Objective</u>: The objective of this project is to develop a broader comprehensive training program for a future call. This proposal will take advantage of the fruitful and lasting collaboration between Institute for clinical effectiveness and health Policy Buenos Aires (IECS) and Human Services in Public Health (HSPH) to improve the creation of training in Peru and other countries in the region.

Project 67 Expenses statement

Mortality associated with the time of onset of highly active antiretroviral therapy (HAART) during the course of treatment for tuberculosis in a cohort of patients with HIV infection in Peru Research project financed by Federal Funds from the United States of America, under direct contract with

National Institute of Health - NIH, through the PARACAS Project.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dr. Gotuzzo, José

	Project execution US\$
Direct costs	
Benefits to employees	2,200
Total Direct costs	2,200
Total Indirect costs - Overhead	
Total costs	2,200

Project Execution Period: From November 2013 to May 2019.

<u>Project General Objective</u>: The objective of this project is to evaluate the effect of the time of onset of HAART in the course of anti-TB treatment on mortality in patients with HIV and TB belonging to the Strategy for the Prevention and Control of STIs / HIV in a hospital center in Peru.

Project 68 Expenses statement

Defining the patterns of antibiotic resistance among pneumococcal isolates in Peru

Research project financed by Federal Funds from the United States of America, under a subcontract with Vanderbilt University Medical Center.

For the period from January 1, 2017 to December 31, 2017.

Researcher: Dra. Ochoa, Theresa

	Project execution US\$
Direct costs	
Equipment and/or supplies	739
Travel expenses	76
Other	1,050
Total Direct costs	1,865
Total Indirect costs - Overhead	64
Total costs	1,929

Project Execution Period: From October 2016 to October 2017.

<u>Project General Objective</u>: The objective of this project is to develop and implement standardized clinical and cognitive tools that can be used in multicultural early-onset dementia studies.

Project 69

Expenses statement

PARACAS Award: Need for Improvements in the Care Retention of Patients with HIV Infection in a Public Reference Hospital in Peru

Research project financed by Federal Funds from the United States of America, under direct contract with National Institute of Health - NIH, through the PARACAS Project.

For the period from January 1, 2017 to December 31, 2017.

Investigadores: Dra. González, Elsa y Dr. Legua, Pedro

	Project execution US\$
Direct costs	
Training	694
Equipment and/or supplies	99
Total Direct costs	793
Total Indirect costs - Overhead	
Total costs	793

Project Execution Period: From September 2015 to May 2019.

<u>Project General Objective</u>: The objective of this project is to evaluate the need for interventions to improve the retention in the care of People living with HIV (PLWHA) in Hospital Nacional Cayetano Heredia (HNCH), identifying and exploring the association between social factors and retention in care in HNCH PLWHA through the use of mixed methods in successive phases.



Paredes, Burga & Asociados Sociedad Civil de Responsabilidad Limitada

Report of the independent auditors on internal control

To the members of the Council University of Universidad Peruana Cayetano Heredia

As part of the audit process of the consolidated expenses statement of sixty nine Research Projects of Universidad Peruana Cayetano Heredia which are financed by Federal Funds from the United States of America, through direct contracts with National Institute of Health (NIH) and indirectly with the NIH through universities of the United States of America for the period from January 1 to December 31, 2017, we have evaluated the internal control system, with the solely purpose to determine the nature, opportunity and extension of our audit procedures in order to express an audit opinion on consolidated expenses statement of sixty nine Research Projects of Universidad Peruana Cayetano Heredia with the rules of audit Government generally accepted of the United States of America, the supplement of compliance the Office of administration and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISA).

As per your knowledge, an entity accounting internal control system has the purpose of safeguard the assets, ensure the transactions are recorded properly and the expenses statements are prepared in accordance with the rules of audit Government generally accepted of the United States of America, the supplement of compliance the Office of administration and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISA). Establishing and maintaining an internal control system is a Management responsibility, who should continuously supervise it in order to conclude that the internal control system function as it was designed, modifying it if it is necessary in accordance with the circumstances, and evaluating the cost and benefits of implementing the control procedures. It is also a Management responsibility maintaining the internal control system needed to ensure the compliance of the University's procedures.

In that sense, we have to address that the internal control system could has limitations. There is a possibility that applying the internal control procedures could arise mistakes and errors due to lack of instructions comprehension, judgment errors, lack of personnel attention, human errors, among others. Furthermore, the procedures which effective operation is based on functions segregation could be elude as consequence of employees collusion. Similarly, the procedures which are design to ensure that transactions are performed in accordance with Management authorization would be ineffective if the decisions are erroneous or irregular. Thus, we cannot ensure all processing errors and irregularities, system deficiencies and not compliance with legal norms has come to our attention in the audit process, thus we do not express an opinion on administrative procedures, on accounting internal control system, and on compliance of legal norms established by Management, and if they have been applied consistently and correctly during the period under revision.



Report of the independent auditors on internal control (continued)

As result of our review, we have detected certain issues, which are presented in the following pages, in order to help the University in the improvement of the procedures and controls. The issues do not necessarily include all the internal control system debilities could have, because, as it was explained in the preceding paragraphs, our evaluation did not have the purpose to express an opinion on such system taken as a whole.

This report is intended for the exclusive use of the Universidad Peruana Cayetano Heredia and National Institute of Health (NIH) and must not be distributed or used by third parties without the authorization of such entities.

Lima, Peru October 1, 2018

Paredes, Burga & Asociedos

Countersigned by:

Tania Arana C.P.C.C. Registration No. 28060

Memorandum of recommendations on issues of internal accounting control and others

Conter	nt		Page
Ι.	Accou 1.	nting and internal control matters Reconciliation of differences between the University's accounting information and	
11.	Follow	operating details from managers and/or principal investigators of research projects	

Memorandum of recommendations on issues of internal accounting control and others

Accounting and internal control matters

I. Accounting and internal control matters

 Reconciliation of differences between the University's accounting information and operating details from managers and/or principal investigators of research projects Description -

We have observed certain differences between the accounting information of the University and operating details from managers and/or principal investigators of the Research Projects, such as the following:

Name of the Project	Total Expense according to accounting department prior to adjustment US\$	Total Expense according to managers and/or principal investigators US\$	Differences US\$
CCASAnet: Caribbean, Central and South			
America Network, see project 40	62,583	39,522	23,061
Training in Infectious Diseases in Peru - Time			
for Capacity Strengthening in Clinical			
Research (Training in Parasitic Diseases and			
Central Nervous System infections), see			
project 5	318,118	334,118	(16,000)
Drug Discovery for Mental Disorders: Preclinical			
Studies of Peruvian Botanicals, see project			
54	16,685	18,278	(1,593)

Due to these differences identified in our review, The General Management Direction analyzed and corrected in its accounting each of these differences to correctly present the expense statements of the research projects for the period from January 1 to December 31, 2017.

Memorandum of recommendations on matters of internal accounting control and other (continued)

Recommendation -

We suggest to the General Direction of Management, monthly carry out a reconciliation of the information between the University accounting and the operating details kept by managers and/or principal investigators of the research projects, in order to detect the generated differences that came out and correct them. Also, establish Controls to verify the compliance with this policy.

This procedure can be performed with the help of the application P-Projects, which is used for keeping the financial information of the research projects.

Management Comments-

During 2018, the general project management is in the process of implementing a monthly reconciliation of the information between the University accounting and the operating details kept by managers and/or principal investigators of the research projects, in order, to identify timely any differences and take the pertinent actions to present the correct balances in the consolidated statements of expenses.

II. Follow-up to recommendations from previous years

Below are the recommendations resulting from previous years, and his current situation:

		Year	Current Situation
1.	Supplies store	2015	Implemented
2.	Consolidated Statements of expenditure	2015	In process
3.	Accountability policy	2015	In process (*)
4.	Accounting and/or administrative personnel in the Research Projects	2015	In process
5.	Use of cash in research projects	2016	Implemented
6.	Cost of staff in research project	2016	In process

(*) The policy is in the process of being approved by the members of the University Council of the University.

Report of Independent Auditors on compliance with the terms of conditions of contracts, subcontracts, laws and regulations applicable to the research projects financed by Federal Funds from the United States of America on contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and National Institute of Health (NIH) and universities of the United States of America, respectively, for the period from January 1 to December 31, 2017.



Paredes, Burga & Asociados Sociedad Civil de Responsabilidad Limitada

Report of independent auditors on compliance with the terms of conditions of contracts, subcontracts, laws and applicable regulations

To Universidad Peruana Cayetano Heredia

1. This report presents the results of the implementation of the agreed upon procedures with you regarding the status of compliance of the terms conditions of contracts, subcontracts, laws, and regulations applicable to the research projects financed by Federal Funds from the United States of America for the period from January 1 to December 31, 2017. Terms of conditions of contracts, subcontracts, applicable laws, and regulations are the responsibility of the General Direction of administration of Universidad Peruana Cayetano Heredia (hereinafter "the University"). Our responsibility is to report on compliance with these terms.

2. Our work was carried out to the extent agreed upon procedures with you, where procedures are detailed in the attached compliance status.

3. Our work only consisted of the review of the compliance of the procedures defined and approved by you, and you consider sufficient for your purposes. We do not assume any responsibility for the adequacy, for its purposes, of the agreed upon procedures with you and executed by us.

4. In this sense, we must specify that the procedures listed later do not constitute an audit or a review made in accordance with standards of Auditing Government Generally Accepted in the United States of America, accordingly we do not express an opinion on the internal control or compliance of terms of conditions of contracts, subcontracts, laws and applicable regulation. Had we performed additional procedures or had we performed an audit or review of the compliance of terms of conditions of contracts, laws and applicable regulation in accordance with the rules of Generally Accepted Government Audit in the United States of America, the supplement of compliance of the Office of administration and compliance (OMB - Office of Management and Budget) of the United States of America - Circular A-133 and the International Standards on Auditing (ISAs), other matters might have come to our attention that would have been reported to you.



Report of independent auditors on compliance with the terms of conditions of contracts, subcontracts, laws and applicable regulations (continued)

5. The results of the execution of agreed upon procedures in relation to the compliance with the terms of conditions of contracts, subcontracts, laws, and regulations applicable to the research projects financed by Federal Funds from the United States of America, for the period from January 1 to December 31, 2017 are presented in the state of compliance attached.

6. The present report is issued for the exclusive use of Universidad Peruana Cayetano Heredia and National Institute of Health (NIH), and must not be distributed or used by third parties without the authorization of such entities.

Lima, Peru October 1, 2018

Paredes, Burga & Asociados

Countersigned by:

Tania Arana C.P.C.C. Registration No. 28060

State of compliance with conditions of the terms of contracts, subcontracts, applicable laws and regulations

Period from January 1 to December 31, 2017

1. Review of the operations of expenses of each project financed by the NIH, including budgeted amounts, the reported expenses and compliance with the procedures laid down in the contracts and subcontracts from January 1, 2017 to December 31, 2017.

Procedures performed -

- We obtained the understanding of the activities carried out by the General Direction of Management in relation to the administration of resources used in the research projects financed by Federal Funds from the United States of America on contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and National Institute of Health (NIH) and universities of the United States of America, respectively. For this purpose, we consider:
 - i. Understand the organizational structure of the University and the financial internal control implemented for the administration of funds from research projects.
 - ii. Review of the terms of contracts, subcontracts, applicable laws and regulations for the administration of funds.
- We obtained the understanding of the preparation of the expenses statement of the research projects for the period from January 1 to December 31, 2017. This understanding included, among others, the following aspects:
 - i. Understanding of the policies, procedures and accounting practices used for the preparation of the expenses statements cited.
 - ii. Review of remittances sent by entities funding University.
- We obtained the understanding of internal controls applied by the General Direction of Management, in relation to the management of projects, procedures for the registration of operations, supporting documentation, and other established control mechanisms for the management of resources.
- We verified the documentation that demonstrates compliance with the clauses in the contracts and subcontracts, during the period under review.
- We made a review of the expenses incurred based on a random sample, to determine whether the documentation is adequate and reasonable.

Results of the performed procedures-

Based on the selected sample, we have verified that the registered expenses have supporting documentation, and the expenditures reported, comply with the terms and conditions established by the funders and are based on budgets delivered by funders.

2. Verified if the expenses incurred by the research projects are adequately justified, with the original documentation that supports them.

Performed procedures -

- We made a review of expenses incurred based on a random sample, to verify whether the expenses incurred are supported by the corresponding documentation.

Results of the performed procedures -

Based on the selected sample we have verified that reviewed expenses have the original documentation that supports them; except the case of some expenses that are supported by supplementary documentation, for example, affidavits, mobility, among other forms.

3. Verified that the income received was used to meet the established objectives.

Performed procedures -

- We obtained the understanding of the objectives of the research projects financed by Federal Funds from the United States of America, through contracts and subcontracts entered into between Universidad Peruana Cayetano Heredia and National Institute of Health (NIH) and universities of the United States of America.
- We made a review of acquisitions of goods and services carried out based on a random sample, to determine whether they contribute to fulfilling the goals settled by each research project.

Results of the performed procedures -

Based on the selected sample, we have verified that the expenses reviewed were related to the fulfillment of the goals set by the research projects.

4. Verified that in the acquisition process were used solid business practices, quotations, were obtained reasonably prices and were settled adequate controls on the qualities and quantities received.

Performed procedures -

- We obtained the understanding of the process of acquisition of goods and services carried out by the research projects.
- We identified the internal controls applied by the University, in relation to the acquisition of goods and services process carried out by the research projects. As part of this process we identified that the University has three modes of acquisition of goods and services: (i) acquisition by competition, which requires a minimum amount of contributions according to a certain scale of prices, (ii) direct negotiation, for goods and services or goods that do not support substitutes and (iii) direct purchase, when there are predetermined prices or it there is no alternative to direct negotiation. In addition to this, we verify that the time of receipt of the goods, the warehouse staff noted that the goods received correspond to a state in the purchase order, which in turn compared to the invoice and corresponding reference guide; in the case of services, the user of the service gives the same compliance.
- We made a review of acquisitions of goods and services based on a random sample, to determine if solid business practices were used in them, quotations, they were obtained reasonable prices and were settled adequate controls on the qualities and quantities received.

Results of the performed procedures -

Based on the selected sample, we verified that the acquisition of goods and services were performed by solid business practices, quotations (in case not be an acquisition by competition) and were obtained reasonable prices, additional to that we verify they had appropriate controls on the qualities and quantities received.

5. In relation to the payroll costs of staff, review: i) if pay rates are a reasonable charge for contracted staff ii) if overtime were imputed to the program and if it was permissible under the terms of the agreements.III) if subsidies and extra benefits received by employees were in accordance with the agreements and the laws and regulations.

Performed procedures -

- We made a review of the monthly expenses of the workers of the research projects based on a random sample, for which we review the payslips and we made a recalculation of the benefits according to the legislation in force in the country.
- We made a review of the types of contracts held with the staff of the research projects, in order to determine that they comply with the legislation in force according to the type of work performed.

Results of the performed procedures -

Based on the selected sample, we did not detect significant mistakes in the recalculations of benefits of selected workers, on the other hand, there were no substantial problems in the form of contracts for workers of the projects; except in the case of some contracts under the form of receipts for fees, on which it was recommended to review the contracts in order to avoid labor contingencies with the Labor Authority.

6. Travel and transportation expenses have the proper supporting documentation and were properly approved.

Performed procedures-

- We obtained the understanding of the process of approval of expenses for travel and transportation for research projects.
- We made a review of travel and transportation expenses based on a random sample, to determine if they have proper support documentation and if they were duly approved.

Results of the performed procedures -

Based on the selected sample, we verified that the expenses for travel and transportation reviewed had adequate support documentation; however, in the case of projects which require transport in areas of difficult access, it is unusual to find companies that provide formal documentation, so these costs are justified by affidavits or forms of mobility. On the other hand, such expenses had all the approvals required before being executed.

7. Basic products (for example, supplies, materials, vehicles, equipment, foodstuffs, tools, etc.) there are or were used for the purposes specified under the terms of the agreements and whether there are control procedures and have been put into operation to properly safeguard products.

Performed procedures -

- We obtained the understanding of the process of approval of the acquisition of basic products.
- We made a review of purchases of basic products based on a random sample, to determine if exists or were used for the purposes specified under the terms of the agreements.
- We made a review of purchases of basic products based on a random sample, to determine if there are control procedures and have been put into operation to properly safeguard products.

Results of the performed procedures -

Based on the selected sample, we verified the purchases of basic products had the documentary support that ensured their existence. Most purchases of them are consumed immediately.

8. Evaluate the outstanding advances to be granted at the University and reimbursements pending to be made at the National Institute of Health (NIH).

Performed procedures-

- We made a review of outstanding advances to be granted based on a random sample.
- We made a review of deliveries to render based on a random sample.
- We made a comparison of the amount assigned to each project versus the amounts disbursed.

Results of the performed procedures -

Based on the selected sample, we verified that the acquisition of goods and services performed, either with money previously delivered or pending of reimbursement by the National Institute of Health (NIH), had all relevant approvals according to the scale of prices determined by the General Direction of Management. Should be noted that in the case of pending refund purchases, they were additionally approved by the General Director of management.

9. Check that in closed projects have been returned the excess cash to the NIH. Also, verify that the assets (inventories, fixed assets, raw materials, etc.) obtained with funds from the program have been disposed in accordance with the terms of the agreements.

Performed procedures-

- We required the list of closed projects during the period 2017.
- We reviewed the contracts, subcontracts, and addenda to determine the closing date of each of the research projects.
- We made a review of research projects closed during the period 2017 based on the selected sample, in order to verify that the corresponding closing reports were made.
- Based on the selected sample, we made a review of assets in order to verify that they have been disposed in accordance with the terms of the agreements.

Results of the performed procedures -

- Based on the list of projects closed during 2017, we verified that the registered closing date of the projects corresponds to the date established in the contracts.
- Based on the selected sample of the projects closed during 2017, we verified that the corresponding closing reports have been made.
- Based on the selected sample of the projects closed during 2017, we verified that the purchased assets were disposed of in according to the terms of the agreements.

EY I Assurance I Tax I Transactions I Advisory

About EY

EY is the global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies over the world. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

For more information, please visit ey.com/pe

©EY All Rights Reserved.